Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
Related Articles
Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL
Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer
Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.
Increased risk of leukemic transformation and worse survival in patients with TP53-mutated MPNs
Shivani Handa, MD, The Ohio State University Wexner Medical Center, Columbus, OH, comments on the prognostic impact of TP53 mutations in patients with myeloproliferative neoplasms…
PEACE-3 Study Results: Efficacy
An expert discusses the key efficacy findings from the PEACE-3 study, including results on radiographic progression-free survival (rPFS) and overall survival (OS), and offers insights…
Fred Hutch announces 10 recipients of the 2025 Harold M. Weintraub Graduate Student Award
Fred Hutch announces 10 recipients of the prestigious 2025 Harold M. Weintraub Graduate Student Award
FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer
CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.
Highlights of ASH®
Get a synopsis of the top hematology research presented at the latest ASH annual meeting and learn how it can help improve your patient management…
2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward
Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.
Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL
Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.
Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC
Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.